Company: IMCR
Filing Date: 2025-02-26
Form Type: 8-K
Source: 0001140361-25-005988
Chunk: 2

Company: Immunocore Holdings plc
Filing Date: 2025-02-26
Form: 8-K
Item: Item 5.02
Chunk 2
---
 will receive an
option grant to purchase ordinary shares of the Company with an aggregate grant date fair value of $400,000, with a grant date of February 25, 2025. The option will vest in equal monthly installments over a three year period such that the option
is fully vested on the third anniversary of the date of grant, subject to Dr. Pao’s continuous service as of each such vesting date. In addition, Dr. Pao will be eligible to receive compensation fees in connection with his service on the Board
and any committees of the Board, as well as additional option grants in the future under the Remuneration Policy.

The Company has entered into its standard indemnity deed for directors with Dr. Pao in connection with his appointment to the Board,
the form of which was filed as Exhibit 10.1 to the Company’s Registration Statement on Form F-1 (File No. 333-252166), initially filed with the Securities and Exchange Commission on January 15, 2021.

There are no arrangements or understandings between Dr. Pao and any other persons pursuant to which he was selected as a director.
There is no family relationship between Dr. Pao and any of the Company’s other directors or executive officers. Since January 1, 2024, Dr. Pao did not have any direct or indirect material interest in any transaction required to be disclosed
pursuant to Item 404(a) of Regulation S-K.